Conclusion
TNBC, breast cancer
BREAST CANCER
This is the first study worldwide, demonstrating that neoadjuvant add-on denosumab over a short-term period of 24 months does not increase the DTC-eradication rate in breast cancer patients treated with NACT. Nevertheless, our results suggest a trend towards a potential predictive effect of DTCs and an increased DTC-eradication by denosumab in TNBC, which warrants further investigation.